# Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

> **NCT02754856** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Carcinoma in the Liver
- Resectable Mass
- Stage IV Colorectal Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT02754856
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-29
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754856, "Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02754856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*